Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Paliperidone XR Tablets (1.5, 3, 6 and 9mg) and Paliperidone Palmitate Injection (117mg/0.75mL, 156mg/mL, 234mg/1.5mL, 39mg/0.25mL, 78mg/0.5mL).
ELC GROUP S.r.o. Czech Republic flag Czech Republic
Abstract ID:
Paliperidone is indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age). Paliperidone palmitate is a long-acting injectable formulation indicated for once-monthly injection after an initial titration period....
Contact Rishi Jacob
Participants
You
Email me a copy of this message

Paliperidone (as Invega) was approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia in 2006. It is marketed for the treatment of schizophrenia and schizoaffective disorder. Paliperidone was approved by the FDA for the treatment of schizoaffective disorder in 2009. It may also be used off-label for other conditions. The long-acting injectable form of paliperidone, marketed as Invega Sustenna in U.S. and Xeplion in Europe, was approved by the FDA on July 31, 2009. It was approved in Europe in 2011 for schizophrenia. In Europe the monthly (every 28 days) injection comes in 50 mg, 75 mg, 100 mg, and 150 mg of paliperidone without the 25 mg injection that is available in the U.S. A dose of 75 mg for a month in an injection is the equivalent of 6 mg per day of paliperidone oral. 6 mg of paliperidone oral (Invega) is equivalent to 2 to 3 mg of risperidone.
Paliperidone Tablets which is a generic form of Invega and paliperidone palmitate, a generic form of Invega Sustenna developed by Janssen Pharmaceuticals had global sales of $573 million and $1.8 billion respectively in 2015.

Type of Business Relationship Sought
Out Licensing
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION